CONTACT US   |  (864) 397-5101

KIYATEC, Inc. expanding operations in Greenville County

KIYATEC, Inc. today announced plans to expand operations in Greenville County. The $5 million investment will create 91 new jobs.

Founded in 2005, KIYATEC, Inc. is a commercial stage cancer diagnostics company born from technology developed at Clemson University, creating transformative solutions for cancer patients using functional precision oncology. KIYATEC, Inc. recently launched its first commercial assay 3D Predict™ Glioma for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.

The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.

“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer including its highly-educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment,” said KIYATEC, Inc. Chief Executive Officer Matt Gevaert, Ph.D.

Located at 2 N. Main Street in Greenville, KIYATEC, Inc.’s downtown facility will allow the company to expand its existing clinical testing operations and drug development services which are co-located with the Cancer Institute at nearby Prisma Health’s Memorial Campus. This new facility will be the anchor tenant of the city of Greenville’s new Innovation District.

The new offices are expected to be operational by January 2022 and the CLIA-certified laboratory by April 2022. Individuals interested in joining the KIYATEC, Inc. team should visit the company’s website.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.